Health ❯ Medicine ❯ Pharmaceuticals

Clinical Trials

Weight Loss Treatments Weight Loss Drugs Phase 3 Studies Alzheimer's Disease Obesity Treatments Cannabis Research Donanemab vs Leqembi Drug Development Patient Data Analysis Breakthrough Therapy Efficacy Studies Weight Reduction Obesity Medication Semaglutide Trial Zepbound Clinical Trials Treatment Development Idiopathic Pulmonary Fibrosis Cardiovascular Disease Male Birth Control Cannabis Extracts Hereditary Angioedema Experimental Treatments ENV-308 Atopic Dermatitis Obesity Drugs Monoclonal Antibodies Duchenne Muscular Dystrophy Rheumatoid Arthritis Obesity Treatment Spinal Cord Injury Treatment Lung Diseases Bladder Cancer Obesity and Diabetes TNX-103 Phase 3 LEVEL Trial Failure

AI-Designed Drug Rentosertib Lowers Biological-Age Signals in Small Trial

The results could point to a druggable way to alter biological aging if larger trials confirm the biomarker changes.

Novo Nordisk’s Semaglutide Eases Childhood Obesity as Heart-Drug Trials Are Halted

Enveda’s ENV-308 Clears Phase 1 Safety Test

Novo Nordisk’s Ziltivekimab Lowers Inflammation but Fails to Reduce Major Heart Events

FDA Staff Flags Major Flaws in Capricor’s Deramiocel Data

Immunovant Shares Surge on Strong Rheumatoid Arthritis Data for IMVT-1402

DOJ Moves State-Licensed Medical Marijuana to Schedule III Ahead of June DEA Hearing

AstraZeneca’s COPD Antibody Tozorakimab Succeeds in Two Phase 3 Trials

Structure’s Oral Obesity Pill Delivers 16.3% Placebo-Adjusted Weight Loss in Phase 2

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Sanofi Pushes Amlitelimab Toward 2026 Filings After Mixed Phase 3 Readouts

Pharvaris’ Oral HAE Drug Deucrictibant Delivers Rapid Relief in Pivotal Phase 3

Cannabis Extract VER-01 Eases Chronic Low Back Pain in Phase 3 Trial

AI-Designed Rentosertib Improves Lung Function in Phase IIa IPF Trial